70 Doppler
Irvine, CA 92618
United States
949 261 2900
https://www.envveno.com
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 31
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Robert A. Berman | CEO & Director | 1,02M | S.O. | 1963 |
Mr. Craig Thomas Glynn | CFO, Treasurer & Secretary | 313,69k | S.O. | 1961 |
Dr. Hamed Alavi Ph.D. | Senior VP & Chief Technology Officer | 384,39k | S.O. | S.O. |
Dr. Marc H. Glickman M.D. | Senior VP & Chief Medical Officer | 491,59k | S.O. | 1949 |
Mr. Warren Hancock | Co-founder | S.O. | S.O. | S.O. |
Dr. Benedict Broennimann M.D. | Chief Medical Officer of Outside of United States | 240k | S.O. | 1957 |
Mr. Andrew Cormack | Chief Commercial Officer | S.O. | S.O. | S.O. |
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
L’ISS Governance QualityScore de enVVeno Medical Corporation en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..